California Blood Bank Society Annual Meeting 2022
Format: 2 videos + 1 pdf, size: 6.36 GB
Course Audience: hematologist
Overview:
Certainly! The California Blood Bank Society (CBBS) held its 2022 Annual Meeting as a virtual event on June 3-4, 2022. Here are the details:
- Agenda: The preliminary agenda included presentations from subject matter experts covering a wide range of topics in Transfusion Medicine and Cell Therapy. Some of the topics discussed were cold stored platelets, cellular therapy, pre-hospital transfusions, monoclonal antibody treatments, and transfusion medicine cases.
- Target Audience: Physicians, nurses, and laboratory professionals were the intended audience for this meeting.
*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below
CBBS-_Annual_Meeting_-_Agenda (PDF Format)
June 3 (Video MP4 Format) (7 hours)
June 4 (Video MP4 Format) (6 hours)
*Detail:
JUNE 3, 2022
8:00 am – Welcome to 2022 CBBS Annual Meeting – CBBS President Suchitra Pandey*
8:05 am – Perkins-Garratty Award Lecture: Prospective Antigen Matching: Effectiveness, Diversity and Equity Dr. Meghan Delaney, DO, MPH
Objectives:
• Explain the impact of prophylactic antigen matching on new RBC alloimmunization in patients with warm autoantibodies.
• Compare different approaches for antigen matching for females and its impact on hemolytic disease of the fetus and newborn (HDFN).
• Relate how the diversity of the patient population may determine access to antigen-matched transfusions and HDFN care.
9:05 am – Cold-Stored Platelets: Current Use and Future Prospects – Dr. James R. Stubbs, MD
Objectives:
• Summarize the differences between cold-stored platelets and room-temperature platelets that should drive preferential use of these products in selected patient populations.
• Illustrate a current use of cold-stored platelets
• Appraise an ongoing research project that could potentially result in the expanded use of cold-stored platelets to benefit patient populations who are not currently receiving these components as part of their care.
10:02 am – Strategies to Maintain an Adequate Platelet Supply – Dr. Suchitra Pandey, MD
Objectives:
• Assess two reasons why the current state of the platelet supply is at risk of critical shortages.
• Examine two strategies to grow the donor pool and increase production of platelets.
10:40 am – Break*
10:45 am – For Here or To-Go? Discussing transfusion in transport. – Michael Baulch, RN, JD & Lee McMurray, MSN
Objectives:
• Examine transfusion needs of critical trauma and medical patients in transport.
• Analyze resuscitation options currently in practice, and their outcomes.
• Compare the benefits of blood component therapy versus whole blood transfusion during transport.
11:30 am – Leadership and Partnership During a National Blood Crisis: Getting Through the Crisis Together – Ross Herron, MD, Divisional Chief Medical Officer, American Red Cross Blood Services & Sarah Barnhard, MD FCAP FASCP, Associate Professor UC Davis
Objectives:
• Contrast three management and allocation strategies implemented by a blood supplier during the largest blood shortage in the past decade
• Summarize the crucial partnership between a hospital and their blood supplier to manage the blood shortage
• Describe the role blood center and hospital leadership played in addressing this national blood crisis.
12:00 pm – Meeting the Transfusion Needs of Patients With Sickle Cell Disease: It’s About Addressing Health Disparities and Access To Donation – Yvette Marie Miller, M.D., ABIHM, & Executive Medical Officer American Red Cross
Objectives:
• Choose at least two effective strategies to increase the recruitment of African American blood donors
• Summarize the important role donor recruitment plays in supporting transfusion needs of sickle cell patients.
12:30 pm – Lunch*
1:00 pm – Auto- vs. alloantibody in a patient with thalassemia – Ariela Edelman, MLS (ASCP)
Objectives:
• Outline the genetics of the Kidd blood group system
• Contrast how molecular methods can be used to distinguish between auto- vs. alloanti-Jka antibodies
• Summarize the limitations of multiple immunohematology testing methodologies
1:22pm – False anemia due to total parenteral nutrition and lipid emulsion contamination – Bethelhem Manakelew
Objectives:
• Analyze the potential for contamination when collecting blood samples.
• Evaluate one facility’s protocol for collecting uncontaminated blood samples.
• Determine the signs of false anemia due to lipid contamination
1:44pm – Therapeutic Response to Apheresis Aids Diagnosis of an Occult Malignancy – Dr. Hehua (Hannah) Huang, MD
Objectives:
• Identify a syndrome that can have several etiologies, including paraneoplastic processes.
• Outline paraneoplastic neurologic disorders (PND).
• Predict common applications of therapeutic apheresis.
2:06pm – Complex Antibody Identification Case Study – Rebecca (Becky) Thomas, MT (ASCP) SBB
Objectives:
• Explain the significance of testing phenotype-matched cells when all test cells are positive and the patient’s auto-control is negative.
• Differentiate two test methods used to facilitate identification of antibodies to high-incidence antigens.
• Appraise the monocyte monolayer assay (MMA).
2:30 pm – Business Meeting*
3:15 pm – Closing Remarks*
June 4, 2022
8:00 am – Welcome and Presentations of the Upton/Hemphill and Thomas Award*
8:15 am – Dr. Goldfinger Tribute – Samuel Pepkowitz, MD, and Louise Smith MPA, MT(ASCP)SBB
8:30 am – Dr. Dennis Goldfinger Award Lecture: Pearls of Wisdom from a Lifelong Fellowship/Friendship with Dr. Dennis Goldfinger – Dr. James Burner, MD
Objectives:
• Describe three clinical and laboratory findings in hyperhemolysis of sickle cell disease.
• Summarize the “two-hit” hypothesis of transfusion-related acute lung injury (TRALI).
• Analyze the potential risk of transfusion-transmitted cytomegalovirus (CMV)
9:15 am – Phasing in RHD Genotyping: Impact on Transfusion Practices – Sunitha Vege, MS
Objectives:
• Compare the different classifications of RHD alleles.
• Outline the strengths and limitations of current molecular methods utilized to identify RHD alleles.
• Conclude the impact of phasing in RHD genotyping on transfusion practices for patients with altered RHD alleles.
10:00 am – Monoclonal antibody interference in blood bank testing – Janet Baez, MT (ASCP)
Objectives:
• Identify two indications for monoclonal antibody therapy
• Examine monoclonal antibody interference in blood bank testing
• Formulate testing options available to resolve monoclonal antibody interference in blood bank testing
10:45 am – Break*
10:55 am – Susanne Ledin Award Lecture: Effective and Efficient Complex Serologic Antibody Identification (OR: Whoa, What Happens after the 3rd Panel?) – Sandra Nance, MS, MASCP, MT(ASCP)SBB
Objectives:
• Describe a complex antibody presentation that may require further investigation.
• Explain how the process of complex antibody identification can be optimized.
• Determine when a complex case resolution exceeds their laboratory’s ability to complete.
11:40 am – New Frontier in Cell Therapy – Dr. Mehrdad Abedi, MD
Objectives:
• Relate at least 2 different disease groups which can be treated with CAR-T cell therapy.
• Outline some of the potential complications of CAR-T cell therapy.
• Identify some of the potential side effects of gene therapy.
12:25 pm – Lunch*
1:05 pm – Polyclonal Regulatory T cell Manufacturing under cGMP: A Decade of Experiences – Dr. Joanna Balcerek, MD, PhD
Objectives:
• Break down key aspects of regulatory T cell manufacturing
• Explain how the quality of regulatory T cell products is assessed
• Compare the impact of independent variables on regulatory T cell manufacturing outcomes
1:35 pm – Ask the Experts – Various Speakers/experts – Moderated by scientific committee chairs
• Compare various opinions offered by expert speakers and resolve unanswered questions
2:35 pm – Closing Remarks*